Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors

Journal of Medicinal Chemistry

Volumn 59, Issue 2, 2016, Pages 655-670

  Rodrigues, Daniel A ^a   Ferreira Silva, Guilherme À ^c   Ferreira, Ana C S ^d   Fernandes, Renan A ^d   Kwee, Jolie K ^d   SantAnna, Carlos M R ^a,b   Ionta, Marisa ^c   Fraga, Carlos A M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 ((2 (4 (DIMETHYLAMINO)BENZOYL) 2 METHYLHYDRAZONO)METHYL) N HYDROXYBENZAMID; 3 ((2 (4 (DIMETHYLAMINO)BENZOYL) 2 METHYLHYDRAZONO)METHYL)BENZOIC ACID; 3 ((2 (4 (DIMETHYLAMINO)BENZOYL)HYDRAZONO)METHYL) N HYDROXYBENZAMIDE; 3 ((2 (4 (DIMETHYLAMINO)BENZOYL)HYDRAZONO)METHYL)BENZOIC ACID; 4 ((2 (4 (DIMETHYLAMINO)BENZOYL) 2 METHYLHYDRAZONO)METHYL) N HYDROXYBENZAMIDE; 4 ((2 (4 (DIMETHYLAMINO)BENZOYL) 2 METHYLHYDRAZONO)METHYL)BENZOIC ACID; 4 ((2 (4 (DIMETHYLAMINO)BENZOYL)HYDRAZONO)METHYL)BENZOIC ACID; 4 (2 (4 (DIMETHYLAMINO)BENZOYL)HYDRAZONO)METHYL) N HYDROXYBENZAMIDE; ALPHA TUBULIN; CASPASE 3; CASPASE 7; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDRAZONE DERIVATIVE; HYDROXAMIC ACID; METHYL 3 ((2 (4 (DIMETHYLAMINO)BENZOYL)HYDRAZONO)METHYL)BENZOATE; METHYL 3 ((2 (4 DIMETHYLAMINO)BENZOYL) 2 METHYLHYDRAZONO)METHYL)BENZOATE; METHYL 4 ((2 (4 (DIMETHYLAMINO)BENZOYL) 2 METHYLHYDRAZONE)METHYL)BENZOATE; METHYL 4 ((2 (4 (DIMETHYLAMINO)BENZOYL)HYDRAZONO)METHYL)BENZOATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASPASE; HDAC6 PROTEIN, HUMAN; HDAC8 PROTEIN, HUMAN; HISTONE DEACETYLASE; REPRESSOR PROTEIN; TUBULIN;

ACETYLATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; ANIMAL; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG DESIGN; ENZYME ACTIVATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDRAZONES; MODELS, MOLECULAR; RATS; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 84969246377     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01525     Document Type: Article

References (72)

1. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705 10.1016/j.cell.2007.02.005
2. Glozak, M. A.; Seto, E. Histone deacetylases and cancer Oncogene 2007, 26, 5420-5432 10.1038/sj.onc.1210610
3. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21 10.1016/j.canlet.2008.08.016
4. Gregoretti, I. V.; Lee, Y.-M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J. Mol. Biol. 2004, 338, 17-31 10.1016/j.jmb.2004.02.006
5. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives Mol. Cancer Res. 2007, 5, 981-989 10.1158/1541-7786.MCR-07-0324
6. Falkenberg, K. J.; Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders Nat. Rev. Drug Discovery 2014, 13, 673-691 10.1038/nrd4360
7. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discovery 2006, 5, 769-784 10.1038/nrd2133
8. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G. M. Histone deacetylase inhibitors: multifunctional anticancer agents Cancer Treat. Rev. 2006, 32, 157-165 10.1016/j.ctrv.2005.12.006
9. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007, 25, 84-90 10.1038/nbt1272
10. Yang, L. P. Romidepsin: in the treatment of T-cell lymphoma Drugs 2011, 71, 1469-1480 10.2165/11207170-000000000-00000
11. Prince, H. M.; Dickinson, M. Romidepsin for cutaneous T-cell lymphoma Clin. Cancer Res. 2012, 18, 3509-3515 10.1158/1078-0432.CCR-11-3144
12. Poole, R. M. Belinostat: first global approval Drugs 2014, 74, 1543-1554 10.1007/s40265-014-0275-8
13. Garnock-Jones, K. P. Panobinostat: first global approval Drugs 2015, 75, 695-704 10.1007/s40265-015-0388-8
14. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116 10.1021/jm0303094
15. Thaler, F.; Mercurio, C. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next ChemMedChem 2014, 9, 523-536 10.1002/cmdc.201300413
16. Kalin, J. H.; Bergman, J. A. Development and therapeutic implications of selective histone deacetylase 6 inhibitors J. Med. Chem. 2013, 56, 6297-6313 10.1021/jm4001659
17. Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P. R.; Mizukami, T.; Nakagawa, H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries J. Med. Chem. 2012, 55, 9562-9575 10.1021/jm300837y
18. Chakrabarti, A.; Oehme, I.; Witt, O.; Oliveira, G.; Sippl, W.; Romier, C.; Pierce, R. J.; Jung, M. HDAC8: a multifaceted target for therapeutic interventions Trends Pharmacol. Sci. 2015, 36, 481-492 10.1016/j.tips.2015.04.013
19. Valenzuela-Fernandez, A.; Cabrero, J. R.; Serrador, J. M.; Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions Trends Cell Biol. 2008, 18, 291-297 10.1016/j.tcb.2008.04.003
20. Oehme, I.; Deubzer, H. E.; Wegener, D.; Pickert, D.; Linke, J. P.; Hero, B.; Kopp-Schneider, A.; Westermann, F.; Ulrich, S. M.; von Deimling, A.; Fischer, M.; Witt, O. Histone deacetylase 8 in neuroblastoma tumorigenesis Clin. Cancer Res. 2009, 15, 91-99 10.1158/1078-0432.CCR-08-0684
21. Wu, J.; Du, C.; Lv, Z.; Ding, C.; Cheng, J.; Xie, H.; Zhou, L.; Zheng, S. The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma Dig. Dis. Sci. 2013, 58, 3545-3553 10.1007/s10620-013-2867-7
22. Park, S. Y.; Jun, J. A.; Jeong, K. J.; Heo, H. J.; Sohn, J. S.; Lee, H. Y.; Park, C. G.; Kang, J. Histone deacetylase 1, 6 and 8 are critical for invasion in breast cancer Oncol. Rep. 2011, 25, 1677-1681 10.3892/or.2011.1236
23. Olson, D. E.; Wagner, F. F.; Kaya, T.; Gale, J. P.; Aidoud, N.; Davoine, E. L.; Lazzaro, F.; Weiwer, M.; Zhang, Y. L.; Holson, E. B. Discovery of the first histone deacetylase 6/8 dual inhibitors J. Med. Chem. 2013, 56, 4816-4820 10.1021/jm400390r
24. Tang, G.; Wong, J. C.; Zhang, W.; Wang, Z.; Zhang, N.; Peng, Z.; Zhang, Z.; Rong, Y.; Li, S.; Zhang, M.; Yu, L.; Feng, T.; Zhang, X.; Wu, X.; Wu, J. Z.; Chen, L. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors J. Med. Chem. 2014, 57, 8026-8034 10.1021/jm5008962
25. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193 10.1038/43710
26. Lima, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design Curr. Med. Chem. 2005, 12, 23-49 10.2174/0929867053363540
27. Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design Chem. Rev. 1996, 96, 3147-3176 10.1021/cr950066q
28. Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. Privileged structures: a useful concept for the rational design of new lead drug candidates Mini-Rev. Med. Chem. 2007, 7, 1108-1119 10.2174/138955707782331722
29. Barreiro, E. J.; Kummerle, A. E.; Fraga, C. A. The methylation effect in medicinal chemistry Chem. Rev. 2011, 111, 5215-5246 10.1021/cr200060g
30. Kummerle, A. E.; Schmitt, M.; Cardozo, S. V.; Lugnier, C.; Villa, P.; Lopes, A. B.; Romeiro, N. C.; Justiniano, H.; Martins, M. A.; Fraga, C. A.; Bourguignon, J. J.; Barreiro, E. J. Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors J. Med. Chem. 2012, 55, 7525-7545 10.1021/jm300514y
31. Tang, C.; Li, C.; Zhang, S.; Hu, Z.; Wu, J.; Dong, C.; Huang, J.; Zhou, H. B. Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer J. Med. Chem. 2015, 58, 4550-4572 10.1021/acs.jmedchem.5b00099
32. Yamada, S.; Morizono, D.; Yamamoto, K. Mild oxidation of aldehydes to the corresponding carboxylic acids and esters: alkaline iodine oxidation revisited Tetrahedron Lett. 1992, 33, 4329-4332 10.1016/S0040-4039(00)74252-3
33. Karabatsos, G. J.; Taller, R. A. Structural studies by nuclear magnetic resonance. V. phenylhydrazones J. Am. Chem. Soc. 1963, 85, 3624-3629 10.1021/ja00905a020
34. Palla, G.; Predieri, G.; Domiano, P.; Vignali, C.; Turner, W. Conformational behaviour and E/Z isomerization of N-acyl and N-aroylhydrazones Tetrahedron 1986, 42, 3649-3654 10.1016/S0040-4020(01)87332-4
35. Hoffmann, K.; Brosch, G.; Loidl, P.; Jung, M. A non-isotopic assay for histone deacetylase activity Nucleic Acids Res. 1999, 27, 2057-2058 10.1093/nar/27.9.2057
36. Schneider, P.; Hosseiny, S. S.; Szczotka, M.; Jordan, V.; Schlitter, K. Rapid solubility determination of the triterpenes oleanolic acid and ursolic acid by UV-spectroscopy in different solvents Phytochem. Lett. 2009, 2, 85-87 10.1016/j.phytol.2008.12.004
37. do Amaral, D. N.; Cavalcanti, B. C.; Bezerra, D. P.; Ferreira, P. M.; Castro Rde, P.; Sabino, J. R.; Machado, C. M.; Chammas, R.; Pessoa, C.; SantAnna, C. M.; Barreiro, E. J.; Lima, L. M. Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues PLoS One 2014, 9, e85380 10.1371/journal.pone.0085380
38. Haggarty, S. J.; Tsai, L.-H. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity Neurobiol. Learn. Mem. 2011, 96, 41-52 10.1016/j.nlm.2011.04.009
39. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications Nature 2000, 403, 41-45 10.1038/47412
40. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 2010, 132, 10842-10846 10.1021/ja102758v
41. Wagner, F. F.; Olson, D. E.; Gale, J. P.; Kaya, T.; Weiwer, M.; Aidoud, N.; Thomas, M.; Davoine, E. L.; Lemercier, B. C.; Zhang, Y. L.; Holson, E. B. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif J. Med. Chem. 2013, 56, 1772-1776 10.1021/jm301355j
42. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases Structure 2004, 12, 1325-1334 10.1016/j.str.2004.04.012
43. Li, L.; Yang, X. J. Tubulin acetylation: responsible enzymes, biological functions and human diseases Cell. Mol. Life Sci. 2015, 72, 4237-4255 10.1007/s00018-015-2000-5
44. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15064-15069 10.1073/pnas.0404603101
45. Biasini, M.; Bienert, S.; Waterhouse, A.; Arnold, K.; Studer, G.; Schmidt, T.; Kiefer, F.; Cassarino, T. G.; Bertoni, M.; Bordoli, L.; Schwede, T. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information Nucleic Acids Res. 2014, 42, W252-W258 10.1093/nar/gku340
46. Benkert, P.; Biasini, M.; Schwede, T. Toward the estimation of the absolute quality of individual protein structure models Bioinformatics 2011, 27, 343-350 10.1093/bioinformatics/btq662
47. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling Bioinformatics 2006, 22, 195-201 10.1093/bioinformatics/bti770
48. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.; Maglathin, R. L.; McLean, T. H.; Bochkarev, A.; Plotnikov, A. N.; Vedadi, M.; Arrowsmith, C. H. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity J. Biol. Chem. 2008, 283, 11355-11363 10.1074/jbc.M707362200
49. El-Serag, H. B. Hepatocellular carcinoma N. Engl. J. Med. 2011, 365, 1118-1127 10.1056/NEJMra1001683
50. Kanno, K.; Kanno, S.; Nitta, H.; Uesugi, N.; Sugai, T.; Masuda, T.; Wakabayashi, G.; Maesawa, C. Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells Oncol. Rep. 2012, 28, 867-873 10.3892/or.2012.1898
51. Ding, G.; Liu, H. D.; Huang, Q.; Liang, H. X.; Ding, Z. H.; Liao, Z. J.; Huang, G. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity FEBS Lett. 2013, 587, 880-886 10.1016/j.febslet.2013.02.001
52. Bergman, J. A.; Woan, K.; Perez-Villarroel, P.; Villagra, A.; Sotomayor, E. M.; Kozikowski, A. P. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth J. Med. Chem. 2012, 55, 9891-9899 10.1021/jm301098e
53. Lakshmaiah, K. C.; Jacob, L. A.; Aparna, S.; Lokanatha, D.; Saldanha, S. C. Epigenetic therapy of cancer with histone deacetylase inhibitors J. Cancer Res. Ther. 2014, 10, 469-478
54. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.-F.; Yao, T.-P. HDAC6 is a microtubule-associated deacetylase Nature 2002, 417, 455-458 10.1038/417455a
55. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO J. 2003, 22, 1168-1179 10.1093/emboj/cdg115
56. Blagosklonny, M. V.; Robey, R.; Sackett, D. L.; Du, L.; Traganos, F.; Darzynkiewicz, Z.; Fojo, T.; Bates, S. E. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol. Cancer Ther. 2002, 1, 937-941
57. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 10014-10019 10.1073/pnas.180316197
58. Zhao, Y.; Tan, J.; Zhuang, L.; Jiang, X.; Liu, E. T.; Yu, Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 16090-16095 10.1073/pnas.0505585102
59. Zhang, X. D.; Gillespie, S. K.; Borrow, J. M.; Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells Mol. Cancer Ther. 2004, 3, 425-435
60. Fandy, T. E.; Shankar, S.; Ross, D. D.; Sausville, E.; Srivastava, R. K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma Neoplasia 2005, 7, 646-657 10.1593/neo.04655
61. Clayden, J.; Greeves, N.; Warren, S. G. Organic chemistry. 2 nd ed.; Oxford University Press: Oxford, NY, 2012.
62. Martinez, C. H.; Dardonville, C. Rapid determination of ionization constants (pKa) by UV spectroscopy using 96-well microtiter plates ACS Med. Chem. Lett. 2013, 4, 142-145 10.1021/ml300326v
63. Monzyk, B.; Crumbliss, A. L. Acid dissociation constants (Ka) and their temperature dependencies (.DELTA.Ha,.DELTA.Sa) for a series of carbon- and nitrogen-substituted hydroxamic acids in aqueous solution J. Org. Chem. 1980, 45, 4670-4675 10.1021/jo01311a024
64. Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture Cancer Commun. 1991, 3, 207-212
65. Zanin, J. L.; Massoni, M.; Santos, M. H.; Freitas, G. C.; Niero, E. L.; Schefer, R. R.; Lago, J. H.; Ionta, M.; Soares, M. G. Caesalpinioflavone, a new cytotoxic biflavonoid Isolated from Caesalpinia pluviosa var. peltophoroides J. Braz. Chem. Soc. 2015, 26, 804-809 10.5935/0103-5053.20150043
66. Mooij, W. T.; Verdonk, M. L. General and targeted statistical potentials for protein-ligand interactions Proteins: Struct., Funct., Genet. 2005, 61, 272-287 10.1002/prot.20588
67. Korb, O.; Stutzle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with PLANTS J. Chem. Inf. Model. 2009, 49, 84-96 10.1021/ci800298z
68. Eldridge, M.; Murray, C.; Auton, T.; Paolini, G.; Mee, R. Empirical scoring functions: I. the development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J. Comput.-Aided Mol. Des. 1997, 11, 425-445 10.1023/A:1007996124545
69. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead, D. R.; Eldridge, M. D. Flexible docking using tabu search and an empirical estimate of binding affinity Proteins: Struct., Funct., Genet. 1998, 33, 367-382 10.1002/(SICI)1097-0134(19981115)33:3<367::AID-PROT6>3.0.CO;2-W
70. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 1995, 245, 43-53 10.1016/S0022-2836(95)80037-9
71. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748 10.1006/jmbi.1996.0897
72. Lovell, S. C.; Davis, I. W.; Arendall, W. B., 3rd; de Bakker, P. I.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. Structure validation by Calpha geometry: phi,psi and Cbeta deviation Proteins: Struct., Funct., Genet. 2003, 50, 437-450 10.1002/prot.10286